基金会MED13L战略研究计划:未来的路线图
Rachel Heilmann1, Anna Pfalzer2,3, Terry Jo Bichell2
1The MED13L Foundation, PO Box 283, Barrington, NJ 08007, USA COMBINEDBrain, Brentwood, TN, USA.
Therapeutic advances in rare disease
|December 2, 2024
概括
一个战略研究计划 (SRP) 指导患者倡导小组开发治疗罕见疾病的治疗方法,如MED13L综合征. 该计划评估了当前的知识和临床前工具,以加快对患者的治疗干预.
科学领域:
- 罕见疾病研究研究.
- 神经发育障碍 神经发育障碍
- 患者倡导 患者倡导
背景情况:
- 患者倡导组织对于推动罕见疾病治疗发展至关重要.
- 专注于MED13L综合征的MED13L基金会与COMBINEDBrain合作,创建了一个战略研究计划 (SRP).
- 该倡议旨在促进对罕见神经发育障碍的临床试验准备.
研究的目的:
- 创建一个客观的MED13L文献评价,包括临床和基础科学知识.
- 评估临床前试验准备工具对于开发MED13L综合征治疗干预措施至关重要.
- 确定扩大知识和促进MED13L研究社区内部合作的机会.
主要方法:
- 对临床文献进行全面的审查,以记录MED13L综合征患者的症状和变异信息.
- 分析科学文献以确定知识差距和研究机会.
- 采访研究人员和临床医生,建立一个协作网络.
- 基于FDA指南的临床前试验准备工具的评估.
- 评估MED13L基金会的基础设施和社区参与.
主要成果:
- 该SRP提供了MED13L综合征的基因型-表型信息的综合总结.
- 确定了在MED13L综合征研究中扩大科学知识的关键领域.
- 通过评估临床前准备,建立了开发治疗方法的框架.
- 突出了MED13L基金会加强以患者为中心的研究的优势和机会.
结论:
- 基金会MED13L的SRP作为优先研究和设定组织目标的重要资源.
- 该计划促进了研究人员,临床医生和基金会之间的合作.
- 它为MED13L综合征社区实现治疗干预提供了明确的方向.
相关概念视频
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...